Roberts C

Beckley Psytech Ltd, Oxford, UK.

4 papers · ORCID

Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.

Seynaeve M, Dunbar F, Hindocha C +4

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine) in patients with treatment-resistant depression.

Roberts C, Seynaeve M, Ermakova AO +5

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for alcohol use disorder: An open-label, phase 2, proof-of-concept, clinical trial.

Marsden J, Kelleher M, Dunbar F +8

Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-<i>N,N</i>-dimethyltryptamine benzoate) in healthy participants.

Rucker JJ, Roberts C, Seynaeve M +6